The novel non-invasive monitoring device rapidly measures and displays an individual’s glucose level within a minute without finger pricking or any pain and the appointment comes in to drive the development of the platform.
FREMONT, CA: Improving the quality of life for all people living with diabetes and prediabetes around the world is one of the areas ripe for innovation, and most businesses are striving to do their bit to lend a hand. To take the advances further ahead, Integrity Applications, the maker of the GlucoTrack, a non-invasive glucose monitoring device for people with Type 2 diabetes and prediabetes, has made Paul V. Goode its President and Chief Operating Officer, effective November 1, 2021.
Since December 17, 2020, Paul has been a member of Integrity's Board of Directors. Goode will resign from the Board of Directors in conjunction with his new position. He will oversee the company's operations, including strategy, design, manufacturing, business, and product development, and begin to construct the U.S. infrastructure in preparation for GlucoTrack's clinical trials in the United States. "I am delighted to take this new role at Integrity," said Goode.
Goode is a seasoned medical device executive with vast experience in all aspects of operations and product development, from concept to global distribution. He has spent a significant amount of time working with innovative diabetes management technologies during his over twenty-year medical device career, including as Vice President of R&D at MetaCure, a neurostimulator device for Type 2 diabetes; Director of Engineering and Algorithm Development at DexCom, a global continuous glucose monitoring company; and Senior Engineer at MiniMed, a maker of integrated insulin pump and continuous glucose sensor systems, before its acquisition. Goode earned his bachelor's, master's, and doctoral degrees from North Carolina State University. He is also named an inventor on more than 150 patents, including more than 100 relating to DexCom's continuous glucose monitoring technology.
"Paul's contributions to date as a member of the Board has been invaluable," said Allen Danzig, member of Integrity's Board of Directors and Chair of the Nominating, Governance and Compensation Committee. "We are excited that Paul is taking a more active, day-to-day role within the company, and we look forward to his guidance and leadership as we continue driving the development of the GlucoTrack platform."